rofecoxib has been researched along with Rhabdomyolysis in 5 studies
Rhabdomyolysis: Necrosis or disintegration of skeletal muscle often followed by myoglobinuria.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The aim of this study was to examine the influence of regulatory measures and other external factors on the rate of ADR reporting in Italy, focusing on four situations occurring in the last 10 years: ACE inhibitor-induced cough; HMG-CoA reductase inhibitors ('statins') and rhabdomyolysis; nimesulide and hepatic toxicity; and cyclo-oxygenase (COX)-2 selective inhibitors ('coxibs') and increase in cardiovascular risk." | 3.74 | Influence of regulatory measures on the rate of spontaneous adverse drug reaction reporting in Italy. ( Conforti, A; Leone, R; Montanaro, N; Moretti, U; Motola, D; Vaccheri, A; Vargiu, A; Velo, G, 2008) |
| "Gitelman's syndrome is manifested by hypokalemic alkalosis, hypomagnesemia, hypocalciuria, normotensive hyperreninemia and hyperaldosteronism." | 1.31 | Successful treatment by cyclooxyenase-2 inhibitor of refractory hypokalemia in a patient with Gitelman's syndrome. ( Farfel, Z; Gurevitz, O; Mayan, H, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Motola, D | 1 |
| Vargiu, A | 1 |
| Leone, R | 1 |
| Conforti, A | 1 |
| Moretti, U | 1 |
| Vaccheri, A | 1 |
| Velo, G | 1 |
| Montanaro, N | 1 |
| Mayan, H | 1 |
| Gurevitz, O | 1 |
| Farfel, Z | 1 |
| Heinzl, S | 1 |
| Roth-Cline, MD | 1 |
| Brown, JS | 1 |
| Kulldorff, M | 1 |
| Chan, KA | 1 |
| Davis, RL | 1 |
| Graham, D | 1 |
| Pettus, PT | 1 |
| Andrade, SE | 1 |
| Raebel, MA | 1 |
| Herrinton, L | 1 |
| Roblin, D | 1 |
| Boudreau, D | 1 |
| Smith, D | 1 |
| Gurwitz, JH | 1 |
| Gunter, MJ | 1 |
| Platt, R | 1 |
5 other studies available for rofecoxib and Rhabdomyolysis
| Article | Year |
|---|---|
Influence of regulatory measures on the rate of spontaneous adverse drug reaction reporting in Italy.
Topics: Adverse Drug Reaction Reporting Systems; Angiotensin-Converting Enzyme Inhibitors; Cardiovascular Di | 2008 |
Successful treatment by cyclooxyenase-2 inhibitor of refractory hypokalemia in a patient with Gitelman's syndrome.
Topics: Adult; Alkalosis; Calcium; Cyclooxygenase Inhibitors; Humans; Hyperaldosteronism; Hypokalemia; Lacto | 2002 |
[Funtional phase IV?].
Topics: Clinical Trials, Phase IV as Topic; Cyclooxygenase Inhibitors; Humans; Lactones; Rhabdomyolysis; Sul | 2005 |
Clinical trials in the wake of Vioxx: requiring statistically extreme evidence of benefit to ensure the safety of new drugs.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Clinical Trials as Topic; Cyclooxygenase 2 Inhibitors; Drug | 2006 |
Early detection of adverse drug events within population-based health networks: application of sequential testing methods.
Topics: Adverse Drug Reaction Reporting Systems; Algorithms; Celecoxib; Competitive Medical Plans; Health Ma | 2007 |